History
A list of downloadable documents created during development.
Background information
-
-
TA214 Breast cancer - bevacizumab (in combination with a taxane): GE decision paper September 2013
-
-
-
TA214 Breast cancer - bevacizumab (in combination with a taxane): Appendix A provisional matrix of stakeholders
-
-
TA214 Breast cancer - bevacizumab (in combination with a taxane): Appendix B proposal paper presented to the Institute's Guidance Executive
-
Breast cancer - bevacizumab (in combination with a taxane): Equality impact assessment
-
Breast cancer - bevacizumab (in combination with a taxane): Equality impact assessment
-
Breast cancer - bevacizumab (in combination with a taxane): Equality impact assessment (PDF 74 KB)
Breast cancer - bevacizumab (in combination with a taxane): final appraisal determination
-
-
Breast cancer - bevacizumab (in combination with a taxane): final appraisal determination
-
-
Breast cancer - bevacizumab (in combination with a taxane): response to consultee, commentator and public comments on the ACD and comments from website consultation
-
-
Breast cancer - bevacizumab (in combination with a taxane): consultee and commentator comments on the ACD
-
Breast cancer - bevacizumab (in combination with a taxane): Roche Products
-
Breast cancer - bevacizumab (in combination with a taxane): Roche Products (PDF 2.98 MB)
-
Breast cancer - bevacizumab (in combination with a taxane): Breakthrough Breast Cancer
-
Breast cancer - bevacizumab (in combination with a taxane): Breakthrough Breast Cancer (PDF 130 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): Department of Health
-
Breast cancer - bevacizumab (in combination with a taxane): Department of Health (PDF 4.2 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): Royal College of Nursing
-
Breast cancer - bevacizumab (in combination with a taxane): Royal College of Nursing (PDF 58 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): Royal College of Pathologists
-
-
Breast cancer - bevacizumab (in combination with a taxane): Kensington and Chelsea PCT
-
Breast cancer - bevacizumab (in combination with a taxane): Kensington and Chelsea PCT (PDF 69 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): Bristol Myers - Squib Pharmaceuticals
-
-
Breast cancer - bevacizumab (in combination with a taxane): Roche Products - new submission
-
-
Breast cancer - bevacizumab (in combination with a taxane): York ERG addendum
-
Breast cancer - bevacizumab (in combination with a taxane): York ERG addendum (PDF 237 KB)
Breast cancer - bevacizumab (in combination with a taxane): appraisal consultation
-
Breast cancer - bevacizumab (in combination with a taxane): appraisal consultation
-
-
Breast cancer - bevacizumab (in combination with a taxane): evaluation report
-
Breast cancer - bevacizumab (in combination with a taxane): pre-meeting briefing
-
Breast cancer - bevacizumab (in combination with a taxane): pre-meeting briefing (PDF 359 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): evidence review group report
-
-
Breast cancer - bevacizumab (in combination with a taxane): evidence review group report - factual accuracy check
-
-
Breast cancer - bevacizumab (in combination with a taxane): non-manufacturer submissions
-
Breast cancer - bevacizumab (in combination with a taxane): Breakthrough Breast Cancer
-
Breast cancer - bevacizumab (in combination with a taxane): Breakthrough Breast Cancer (PDF 123 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): Breast Cancer Care
-
Breast cancer - bevacizumab (in combination with a taxane): Breast Cancer Care (PDF 65 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): Royal College of Nursing
-
Breast cancer - bevacizumab (in combination with a taxane): Royal College of Nursing (PDF 3.5 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): Royal College of Physicians (NCRI Breast Clinical Studies Group/RCP/RCR/ACP/JCCO)
-
-
Breast cancer - bevacizumab (in combination with a taxane): NHS Kensington and Chelsea
-
Breast cancer - bevacizumab (in combination with a taxane): NHS Kensington and Chelsea (PDF 55 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): NHS Milton Keynes
-
Breast cancer - bevacizumab (in combination with a taxane): NHS Milton Keynes (PDF 73 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): manufacturer submissions
-
Breast cancer - bevacizumab (in combination with a taxane): response from manufacturer 1
-
-
Breast cancer - bevacizumab (in combination with a taxane): response from manufacturer 2
-
Breast cancer - bevacizumab (in combination with a taxane): response from manufacturer 2 (PDF 85 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): NICE letter 1
-
Breast cancer - bevacizumab (in combination with a taxane): NICE letter 1 (PDF 137 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): NICE letter 2
-
Breast cancer - bevacizumab (in combination with a taxane): NICE letter 2 (PDF 112 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): Roche products
-
Breast cancer - bevacizumab (in combination with a taxane): Roche products (PDF 2.98 MB)
-
Breast cancer - bevacizumab (in combination with a taxane): expert written personal statements
-
Breast cancer - bevacizumab (in combination with a taxane): Ellis
-
Breast cancer - bevacizumab (in combination with a taxane): Ellis (PDF 17 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): Leadbeater
-
Breast cancer - bevacizumab (in combination with a taxane): Leadbeater (PDF 19 KB)
-
Breast cancer - bevacizumab (in combination with a taxane): Sinclair
-
Breast cancer - bevacizumab (in combination with a taxane): Sinclair (PDF 27 KB)
Breast cancer - bevacizumab (in combination with a taxane): final scope
-
Breast cancer - bevacizumab (in combination with a taxane): final scope
-
Breast cancer - bevacizumab (in combination with a taxane): final scope (PDF 27 KB)
Breast cancer - bevacizumab (in combination with a taxane): final matrix
-
Breast cancer - bevacizumab (in combination with a taxane): final matrix
-
Breast cancer - bevacizumab (in combination with a taxane): final matrix (PDF 33 KB)
Breast cancer - bevacizumab (in combination with a taxane): Institute's response to comments on the draft scope
-
Breast cancer - bevacizumab (in combination with a taxane): Institute's response to comments on the draft scope
-
Breast cancer - bevacizumab (in combination with a taxane): Institute's response to comments on the draft matrix
-
Breast cancer - bevacizumab (in combination with a taxane): Institute's response to comments on the draft matrix
-